Status:
COMPLETED
Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Conditions:
Smoking Cessation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
There are currently over 11 million cancer survivors in the U.S. and survival rates are increasing. Unfortunately, 10-30% of cancer patients are current smokers at the time of diagnosis, and many of t...
Detailed Description
Specific Aims Aim 1: To compare the effectiveness of two tobacco treatments that are integrated into cancer care in producing tobacco abstinence at 6 months. Aim 2: To explore: a) mechanisms through...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Adult men and women may participate in this study if he/she meet the following requirements:
- Current, new\* patient at one of our three participating study sites: Massachusetts General Hospital (MGH) Cancer Center, Memorial Sloan Kettering Cancer Center (MSKCC), or Dana-Farber Cancer Institute (DFCI);
- Currently with suspected or newly diagnosed cancer (thoracic, breast, genitourinary, gastrointestinal, head and neck, gynecologic, lymphoma, melanoma);
- Has smoked a cigarette, even a puff, in the past 30 days;
- Is willing to consider trying to quit smoking using counseling and/or smoking cessation medication;
- Is English or Spanish speaking (MGH); English speaking (MSK; DFCI);
- Has regular telephone access.
- \[\*Patients will be considered "new" and eligible under the following conditions:
- if they are attending approximately one of their first 4 visits or are within approximately 3 months of the initial visit date with their primary oncologist at the Massachusetts General Hospital (MGH) Cancer Center, Memorial Sloan Kettering Cancer Center (MSKCC), or Dana-Farber Cancer Institute (DFCI) for suspected or recently diagnosed cancer;
- if they come to the MGH, MSKCC, or DFCI for a second opinion, the patient opts to receive their cancer treatment at any of these institutions;
- if they have a past cancer diagnosis, they are currently faced with a local and distant recurrence of tumors;
- if they have been treated previously for other types of cancer, they are currently faced with a new form of cancer.\]
- EXCLUSION CRITERIA:
- In an effort to be as inclusive as possible, a patient will be excluded only if he/she:
- Is NOT currently receiving or has no intentions to receive care at one of three participating cancer treatment centers: Massachusetts General Hospital Cancer Center, Memorial Sloan Kettering Cancer Center, or Dana-Farber Cancer Institute (DFCI);
- Is currently psychiatrically unstable or otherwise unable to provide informed consent as determined by study investigators or oncology clinician;
- Is not English or Spanish speaking;
- Is medically ineligible (as determined by their treating physician);
- Has insufficient comprehension/literacy.
- ADDITIONAL INFORMATION:
- Participant inclusion/exclusion is not based on use of smoking cessation medication -- he/she may decide not to use any smoking cessation medication and still participate in the study. Patients deemed ineligible will be referred to the state quit line.
- Patients interested in participating in the study should contact the appropriate contact person, based on whether they are a current patient at the MGH, MSKCC, or DFCI.
Exclusion
Key Trial Info
Start Date :
September 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2018
Estimated Enrollment :
303 Patients enrolled
Trial Details
Trial ID
NCT01871506
Start Date
September 1 2013
End Date
May 1 2018
Last Update
August 28 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
3
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065